List of Excipients in Branded Drug CYANOCOBALAMINE

Generic Drugs Containing CYANOCOBALAMINE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	cyanocobalamine injection	0404-9995	ACETIC ACID
Henry Schein Inc	cyanocobalamine injection	0404-9995	BENZYL ALCOHOL
Henry Schein Inc	cyanocobalamine injection	0404-9995	HYDROCHLORIC ACID
Henry Schein Inc	cyanocobalamine injection	0404-9995	SODIUM ACETATE
Henry Schein Inc	cyanocobalamine injection	0404-9995	SODIUM CHLORIDE
Henry Schein Inc	cyanocobalamine injection	0404-9995	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in CYANOCOBALAMINE?

# Of NDCs	Excipient
2	ACETIC ACID
2	BENZYL ALCOHOL
2	HYDROCHLORIC ACID
2	SODIUM ACETATE
2	SODIUM CHLORIDE
2	SODIUM HYDROXIDE

Cyanocobalamin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Cyanocobalamin is a mature vitamin B12 active ingredient with low active pharmaceutical ingredient cost, broad regulatory familiarity, and multiple delivery routes. Commercial differentiation depends primarily on bioavailability, tolerability, packaging stability, convenience, and channel positioning rather than on new chemical entity protection. The strongest opportunities are in oral products for adherence, low-volume parenteral products, nasal delivery, pediatric formulations, vegan-friendly supplements, and combination products that address specific deficiency populations.

What is the commercial and regulatory position of cyanocobalamin?

Cyanocobalamin is a synthetic form of vitamin B12 used to prevent or treat vitamin B12 deficiency. It is available as a prescription drug, over-the-counter product, dietary supplement, injectable product, nasal formulation, and ingredient in multivitamin products.

The principal commercial characteristics are:

Attribute	Cyanocobalamin position
Active ingredient	Vitamin B12, synthetic cobalamin
Main therapeutic use	Prevention and treatment of vitamin B12 deficiency
Common routes	Oral, sublingual, intranasal, intramuscular, subcutaneous
Prescription status	Injectable and certain nasal products
OTC status	Tablets, capsules, lozenges and dietary supplements
Generic competition	Extensive for conventional injections and oral products
Primary differentiation	Route, dose, excipient system, packaging, compliance and claims
Active-ingredient patent risk	Low; cyanocobalamin has been commercially established for decades
Formulation patent opportunity	Selective; strongest for delivery systems, stability, modified release and combination products
Biosimilar risk	None; cyanocobalamin is a small-molecule vitamin, not a biologic

Cyanocobalamin is listed in the United States Pharmacopeia, and FDA-approved products use established pharmaceutical excipients such as sodium chloride, benzyl alcohol, sodium hydroxide or hydrochloric acid for pH adjustment, and water for injection. Product-specific composition must be confirmed against the applicable FDA labeling and regulatory filing. [1,2]

Which cyanocobalamin dosage forms offer the strongest opportunities?

The most attractive formulation strategy depends on the target population and route of administration. Conventional injectable products are technically straightforward but highly price competitive. Oral and intranasal products offer more room for differentiated positioning.

Oral tablets, capsules and softgels

Oral cyanocobalamin is the largest and most accessible product category. Typical products contain cyanocobalamin at doses ranging from microgram quantities in multivitamins to milligram quantities in high-dose supplements.

Common excipient classes include:

• Fillers such as microcrystalline cellulose, lactose, mannitol and dibasic calcium phosphate
• Binders such as povidone, hydroxypropyl cellulose and pregelatinized starch
• Disintegrants such as croscarmellose sodium, sodium starch glycolate and crospovidone
• Lubricants such as magnesium stearate, stearic acid and silicon dioxide
• Film coatings based on hypromellose, polyethylene glycol and titanium dioxide
• Sweeteners and flavors for chewable or orally disintegrating products

The central technical issue is not generally chemical instability of cyanocobalamin alone. It is control of product performance across a low-dose formulation, especially content uniformity, blend segregation, dissolution and light exposure.

For low-dose tablets, geometric dilution and controlled particle-size distribution are important. Cyanocobalamin may be present at a very low concentration relative to the excipient mass, creating a content-uniformity risk. Direct compression can reduce processing steps, but wet granulation can improve blend uniformity when the powder properties are poor.

A commercially differentiated oral product could use:

1. A small, swallowable tablet for older adults.
2. A fast-dissolving tablet for patients with swallowing difficulty.
3. A chewable product with low sugar and no artificial colors.
4. A high-dose product positioned for patients with absorption concerns.
5. A vegan capsule using hypromellose rather than gelatin.
6. A combination product with folic acid, iron or other B vitamins, subject to claim and safety review.

Sublingual and orally disintegrating products

Sublingual marketing is common in the supplement sector, but the label claim should not imply clinically meaningful transmucosal absorption without supporting evidence. Many products marketed as sublingual tablets may primarily dissolve in the mouth and then be swallowed.

Excipient selection should prioritize:

• Rapid wetting
• Low tablet friability
• Palatable taste
• Controlled mouthfeel
• Low residual moisture
• Adequate packaging protection

Mannitol is frequently useful for mouthfeel and cooling sensation. Crospovidone can support rapid disintegration. Low-substituted hydroxypropyl cellulose and microcrystalline cellulose can improve tablet structure. Sweeteners such as sucralose, steviol glycosides or acesulfame potassium can reduce the metallic or vitamin-like taste associated with some B-vitamin formulations.

The commercial opportunity is strongest in adherence-oriented products, but the product should avoid overstating the pharmacokinetic advantage of sublingual delivery unless comparative data support it.

Intranasal cyanocobalamin

Intranasal cyanocobalamin has been commercialized as a prescription product for maintenance therapy in selected patients after correction of deficiency. The historical U.S. product Nascobal is a cyanocobalamin nasal gel. Its formulation uses a nasal gel vehicle designed to retain the dose on the nasal mucosa. [3]

Nasal products require a more demanding excipient strategy than tablets. Key attributes include:

• Mucosal tolerability
• Viscosity and retention
• Spray or pump performance
• Preservative control
• Microbial limits
• Dose uniformity
• Compatibility with container-closure systems
• Absence of unacceptable nasal irritation

Potential excipient systems include aqueous buffers, viscosity modifiers, humectants, surfactants and preservatives. Each excipient must be evaluated for nasal-route suitability rather than relying only on oral-use precedent. The formulation must also control pH and osmolality within a tolerable nasal range.

The opportunity is a convenient maintenance product for patients who prefer to avoid injections. The principal barriers are clinical evidence, device performance, nasal tolerability and reimbursement. A nasal formulation with a preservative-free multidose or unit-dose presentation could create differentiation, but packaging complexity and microbial-control requirements increase development cost.

Injectable cyanocobalamin

Cyanocobalamin injection is a mature generic category. Products are commonly supplied in multidose vials or ampules and administered intramuscularly or subcutaneously. FDA labeling for cyanocobalamin injection identifies water for injection and may include sodium chloride, pH adjusters and antimicrobial preservatives depending on the product presentation. Benzyl alcohol is used in some multidose products but creates an avoidable concern for neonates and certain pediatric populations. [1,2]

A formulation strategy should distinguish between:

• Preserved multidose vials for institutional use
• Preservative-free single-dose ampules or prefilled syringes
• Low-volume presentations for home administration
• High-concentration products intended to reduce injection volume
• Ready-to-use products for specialty clinics

The principal commercial opportunity is operational rather than pharmacological. A prefilled syringe can reduce preparation time and dosing errors, while a preservative-free presentation can support pediatric, neonatal or preservative-sensitive use. The product must meet container-closure, extractables and leachables, sterility, particulate and stability requirements.

What excipients are most relevant to cyanocobalamin stability?

Cyanocobalamin formulation development should focus on light protection, pH control, oxidation risk, moisture management and interaction with other active ingredients.

Light protection

Cyanocobalamin is light sensitive. Light exposure can produce degradation and discoloration, particularly in solution formulations. Amber glass, opaque plastic, foil overwraps and light-resistant secondary packaging can reduce exposure.

Packaging may offer a stronger commercial advantage than a novel excipient. A blister with an opaque barrier, an amber multidose vial or an individually wrapped unit-dose sachet can extend shelf life without materially changing the formulation.

pH and buffer selection

Aqueous formulations require controlled pH. Buffer selection must balance chemical stability, injection or nasal tolerability, and compatibility with the container. Common candidates include phosphate, citrate and acetate systems, although the final choice must be supported by stability and route-specific tolerability data.

Over-buffering can create problems if the product is administered parenterally or intranasally. A low-buffer-capacity system may reduce irritation but provide less resistance to pH drift.

Antioxidants and chelators

Antioxidants and chelating agents may be evaluated where oxidation or trace-metal catalysis affects stability. Their use should be justified by degradation data and compatibility studies. An unnecessary antioxidant can create regulatory and formulation complexity without improving shelf life.

For injectable products, every additional excipient increases the burden of safety qualification, compendial control and container-closure assessment. The preferred strategy is usually the smallest excipient system that achieves the required stability and performance.

Moisture and solid-state control

Oral products should be evaluated for moisture uptake, especially when using hygroscopic excipients or high-surface-area powders. Moisture can affect tablet hardness, disintegration, color and assay uniformity.

Desiccants, high-barrier bottles, alu-alu blisters and low-permeability films can protect the product. These measures are particularly relevant for orally disintegrating tablets, chewables and powder-filled capsules.

What formulation patents protect cyanocobalamin products?

The core cyanocobalamin molecule is not a practical source of new exclusivity. Commercial protection is more likely to arise from formulation, delivery, device or combination claims.

Potential claim categories include:

Patent category	Potentially protectable subject matter	Commercial strength
Nasal delivery	Gel composition, retention profile, spray device and dosing regimen	Medium to high if clinically differentiated
Oral rapid disintegration	Tablet composition, disintegration time and manufacturing process	Low to medium
Stability	Specific pH, antioxidant, buffer or packaging combination	Medium if unexpected stability is demonstrated
Prefilled injection	Syringe configuration, concentration and storage system	Medium
Modified release	Matrix, coating or multiparticulate system	Medium, but limited clinical need
Combination product	Cyanocobalamin with folate, iron or other actives	Low to medium
Pediatric formulation	Preservative-free composition, dose flexibility and palatability	Medium
Manufacturing process	Granulation, blending, sterilization or filling process	Low to medium unless difficult to design around

A patent strategy should avoid claiming only the use of conventional excipients at ordinary concentrations. Such claims face significant obviousness and enablement challenges. Stronger protection generally requires a defined performance result, such as an unexpected stability profile, improved nasal retention, reduced injection pain, superior content uniformity or a device-formulation combination.

When does cyanocobalamin lose exclusivity?

Cyanocobalamin has no meaningful new-molecule exclusivity timeline in the United States. Conventional cyanocobalamin injections and oral products have long been exposed to generic and supplement competition.

The relevant exclusivity framework depends on the product category:

Product type	Main regulatory framework	Exclusivity profile
Prescription injection	NDA or ANDA under the Federal Food, Drug, and Cosmetic Act	Generic competition; product-specific patents and regulatory exclusivity may apply
Prescription nasal product	NDA	Potential formulation, method-of-use or device patents
OTC supplement	Dietary supplement framework	No FDA drug exclusivity; differentiation relies on brand, evidence and distribution
OTC drug product	Applicable OTC requirements and labeling	Monograph or enforcement-discretion status depends on product claims
Combination product	Drug, device or both	Exclusivity depends on the regulated components and claims

Paragraph IV challenges are possible where a cyanocobalamin NDA contains listed patents, but the conventional active ingredient itself does not create a significant barrier. Generic applicants are more likely to challenge formulation, device or method-of-use patents than an active-ingredient patent.

What is the Orange Book status of cyanocobalamin?

The FDA Orange Book is relevant to approved prescription drug products, not to ordinary dietary supplements. Cyanocobalamin injection products may appear as approved prescription products or generic equivalents depending on the product and sponsor. Orange Book patent listings are product-specific and should be reviewed by application number rather than by active ingredient alone. [4]

An Orange Book review should examine:

• Approved application number
• Reference-listed drug status
• Listed patents
• Patent expiration dates
• Pediatric exclusivity
• Paragraph IV certifications
• Suitability petitions
• Therapeutic equivalence ratings
• Discontinued-product status

A supplement brand cannot rely on Orange Book listing to establish market exclusivity. Its defensibility must come from trademarks, formulation know-how, clinical substantiation, distribution, quality systems and consumer recognition.

Which companies are competing in cyanocobalamin?

Competition spans generic pharmaceutical manufacturers, branded prescription sponsors, contract manufacturers, dietary supplement companies and private-label distributors.

The market is fragmented across:

• Generic injectable suppliers
• Hospital and clinic wholesalers
• Retail pharmacy brands
• E-commerce supplement brands
• Multivitamin manufacturers
• Specialty nutrition companies
• Compounding pharmacies
• Contract development and manufacturing organizations

Manufacturers with sterile filling capacity have an advantage in injectable and nasal development. Companies with consumer-health distribution have an advantage in chewable, gummy, sublingual and vegan products. The strongest commercial position depends on the route and channel rather than on cyanocobalamin ownership.

What generic launch risks exist for a new cyanocobalamin product?

A new cyanocobalamin product faces high substitution risk when it is an undifferentiated tablet, capsule or injection. Generic and private-label alternatives can compete on price immediately or shortly after launch.

Key launch risks include:

1. Low switching costs for oral products.
2. Limited physician dependence on a branded cyanocobalamin product.
3. Reimbursement pressure for injections.
4. Consumer confusion between drugs and supplements.
5. Difficulty proving clinical superiority for high-dose oral products.
6. Narrow margins after retailer and distributor discounts.
7. Stability failures caused by light, moisture or oxygen.
8. Manufacturing complexity for sterile or nasal products.
9. Claims restrictions for dietary supplements.
10. Weak patent protection around routine excipient combinations.

A product can reduce these risks through a clear use case, such as preservative-free pediatric injection, a clinically supported nasal maintenance product, a low-volume prefilled syringe, or a palatable formulation designed for long-term adherence.

How should an excipient strategy differ by target population?

Older adults

Older adults are more likely to have swallowing difficulty, polypharmacy and adherence challenges. Small tablets, orally disintegrating tablets, liquid preparations and easy-open packaging are commercially relevant. Sugar-free and low-sodium options can support broader use.

Vegans and vegetarians

Cyanocobalamin itself is compatible with vegan positioning, but gelatin capsules, lactose and animal-derived processing aids can undermine the claim. Hypromellose capsules and plant-based excipient systems support vegan labeling, subject to supplier documentation.

Pediatric patients

Pediatric products require careful control of flavor, sweetener exposure, dose flexibility and preservative selection. Benzyl alcohol should be avoided where the target population or route makes it clinically inappropriate. Unit-dose oral liquids or preservative-free presentations can create a differentiated product.

Bariatric and malabsorption populations

High-dose oral products are commonly marketed for patients with absorption concerns. The product should distinguish between a pharmacological dose strategy and a claim that the formulation improves absorption. A formulation patent is difficult to defend unless pharmacokinetic or clinical data demonstrate a meaningful advantage.

Institutional and home-injection users

Prefilled syringes, low dead-space devices, clear labeling and reduced injection volume can create operational value. The excipient system should be optimized for syringe compatibility, particulate control and storage stability.

How strong is the cyanocobalamin patent estate?

The overall patent estate is weak for the active ingredient and conventional dosage forms. It can be moderate for route-specific or device-enabled products.

Estate component	Strength assessment
Cyanocobalamin composition of matter	Very weak or unavailable as a current exclusivity platform
Conventional oral tablet	Weak
Conventional injection	Weak
Nasal gel or nasal spray	Moderate, depending on surviving claims
Prefilled syringe	Moderate for device-specific claims
Preservative-free pediatric product	Moderate if supported by meaningful technical differentiation
Novel combination therapy	Variable
Manufacturing know-how	Potentially valuable but difficult to enforce
Packaging and stability system	Moderate if unexpected shelf-life data support the claims

Patent diligence should include the USPTO Patent Center, FDA Orange Book, FDA Approved Drug Products with Therapeutic Equivalence Evaluations, WIPO Patentscope and national registers in target markets. Patent term, maintenance fees, terminal disclaimers, ownership assignments and claim scope must be checked before relying on any apparent formulation patent. [4-7]

What licensing deals and partnering opportunities exist?

Licensing value is more likely to attach to delivery technology than to cyanocobalamin itself. Potential deal structures include:

• In-licensing of nasal or buccal delivery platforms
• Co-development of prefilled sterile products
• Private-label supply agreements for vegan or clean-label supplements
• Regional distribution rights for prescription nasal products
• Contract manufacturing of preservative-free injections
• Brand licensing for clinically substantiated deficiency products
• Combination-product partnerships with iron, folate or gastrointestinal therapies

The most defensible deal asset is a product with validated manufacturing, regulatory precedent, differentiated packaging and channel access. A patent application without stability, pharmacokinetic or commercial data has limited licensing value.

What FDA regulatory issues apply to cyanocobalamin excipients?

FDA review focuses on the complete formulation, route, dosage form, manufacturing process and labeling. The FDA Inactive Ingredient Database can support excipient precedent, but database presence does not guarantee approval for a new route, concentration or patient population. [8]

Critical regulatory workstreams include:

• Excipient identity and grade
• Supplier qualification
• Compendial compliance
• Elemental impurities
• Residual solvents
• Microbial limits
• Preservative effectiveness
• Sterility assurance for injections
• Extractables and leachables
• Photostability
• Container-closure integrity
• Stability under proposed storage conditions
• Content uniformity for low-dose oral products
• Route-specific local tolerability

For dietary supplements, the regulatory emphasis shifts toward current good manufacturing practice, identity and purity testing, structure-function claims, adverse-event reporting and truthful labeling. FDA does not preapprove dietary supplements for safety or efficacy in the same manner as prescription drugs. [9]

What are the best commercial opportunities for cyanocobalamin?

The strongest opportunities are:

1. Preservative-free, single-dose injectable products for pediatric, hospital and specialty use.
2. Prefilled syringes that reduce preparation and administration burden.
3. Nasal maintenance therapy with improved retention, dosing consistency or patient convenience.
4. Vegan, sugar-free and allergen-controlled oral products.
5. Orally disintegrating tablets for older adults and patients with dysphagia.
6. High-quality private-label products with verified potency and stability.
7. Combination products targeted to documented deficiency risks.
8. Light-protective packaging that provides longer shelf life or improved in-use stability.
9. Clinically substantiated products for bariatric or malabsorption populations.
10. Regional licensing of differentiated formulations where local access to injections is limited.

Generic injections and undifferentiated tablets remain difficult categories because price and availability dominate purchasing decisions. A new product needs a measurable advantage in adherence, administration, stability, tolerability, or distribution economics.

Key Takeaways

• Cyanocobalamin is a mature, low-cost active ingredient with extensive generic and supplement competition.
• The active ingredient provides little practical patent protection.
• Excipient strategy should be route-specific and focused on light stability, pH, moisture, content uniformity, tolerability and packaging.
• Oral products offer the lowest technical barrier but also the weakest differentiation.
• Nasal, preservative-free injectable and prefilled-syringe products offer stronger commercial positioning.
• Patent value is concentrated in delivery systems, device combinations, stability solutions and clinically supported formulation performance.
• There is no biosimilar risk because cyanocobalamin is not a biologic.
• Orange Book analysis applies to prescription products, not ordinary dietary supplements.
• Licensing opportunities are strongest where formulation know-how is combined with regulatory readiness and channel access.
• A successful launch requires a defined target population and a measurable advantage over low-cost oral and injectable alternatives.

FAQs

Is cyanocobalamin compatible with vegan pharmaceutical products?

Yes. The active ingredient can be formulated in vegan products, but the manufacturer must verify that capsules, coatings, processing aids and other excipients do not contain animal-derived materials.

Which is more commercially attractive, cyanocobalamin or methylcobalamin?

Cyanocobalamin generally has stronger cost, supply and regulatory precedent. Methylcobalamin can support premium supplement positioning, but the commercial advantage depends on evidence, claims discipline and consumer preference.

Can a cyanocobalamin tablet receive new patent protection?

A conventional tablet is unlikely to support strong patent protection. A formulation may be patentable if it demonstrates non-obvious technical performance, such as improved stability, absorption, taste, disintegration or manufacturing control.

Does cyanocobalamin require an antioxidant?

Not universally. The need depends on formulation composition, oxygen exposure, light exposure, pH, impurities and stability data. Unnecessary antioxidants add regulatory and compatibility burdens.

Are cyanocobalamin gummies a strong commercial opportunity?

Gummies can attract consumers who dislike tablets, but they introduce stability, potency, moisture, sugar, sweetener and packaging challenges. A sugar-free, low-moisture and well-protected gummy has greater differentiation than a conventional high-sugar product.

References

1. DailyMed. (n.d.). Cyanocobalamin injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Cyanocobalamin injection labeling and regulatory information. https://www.accessdata.fda.gov/

3. DailyMed. (n.d.). Nascobal cyanocobalamin nasal spray and nasal gel labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

6. World Intellectual Property Organization. (n.d.). PATENTSCOPE. https://patentscope.wipo.int/

7. U.S. Food and Drug Administration. (n.d.). Patent listings and certifications in approved drug applications. https://www.fda.gov/

8. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

9. U.S. Food and Drug Administration. (n.d.). Dietary supplements and current good manufacturing practices. https://www.fda.gov/food/dietary-supplements.